Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Diclofenac diethylammonium 1.16% gel
1003020AFAAAAAA
|
Diclofenac diethylammonium | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 336,867 |
|
Diclofenac diethylammonium 2.32% gel
1003020AFAAABAB
|
Diclofenac diethylammonium | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 108,248 |
|
Voltarol 1.16% Emulgel
1003020AFBBAAAA
|
Voltarol Emulgel | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 85,888 |
|
Voltarol 12 Hour Emulgel P 2.32% gel
1003020AFBBADAB
|
Voltarol Emulgel | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 27,082 |
|
Voltarol Osteoarthritis Joint Pain Relief 1.16% gel
1003020AFBBABAA
|
Voltarol Emulgel | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 5,357 |
|
Voltarol Back & Muscle Pain Relief 1.16% gel
1003020AFBBACAA
|
Voltarol Emulgel | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 1,008 |
|
Motusol Max 12 Hour Pain Relief 2.32% gel
1003020AFBCACAB
|
Motusol | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 4 |
|
Motusol 1.16% gel
1003020AFBCAAAA
|
Motusol | Diclofenac diethyl | Musculoskeletal and Joint Diseases | 3 |
|
Care Pain Relief 2.32% gel
1003020AFBDAAAB
|
Care Pain Relief | Diclofenac diethyl | Musculoskeletal and Joint Diseases | No data available |
|
Motusol Max 2.32% gel
1003020AFBCABAB
|
Motusol | Diclofenac diethyl | Musculoskeletal and Joint Diseases | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.